Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia

Inclusion Criteria: * Age≥18； * The new diagnosis of CML patients in six months； * No proof of extra-medullary infiltration of leukemia； * ECOG PS score：0-2； * Hepatic and renal functions are normal，Serum bilirubin≤1.5\*ULN, serum ALT and AST≤2.5\*ULN, serum Cr≤1.5\*ULN; * Do not receive the treatment of anti-CML； * Subjects signed informed consent form in line with GCP requirements。 Exclusion Criteria: * Pregnant or lactating women； * Received TKIs any time before； * Failure to control systemic infection or multiple organ failure； * According to the investigator's judgment, there are concomitant diseases with a serious safety hazard or affect the patients completed the study； * Being diagnosed with other malignancies in the prior 12 months； * Have a history of neurological or psychiatric disorders, including epilepsy or dementia； * Known or suspected allergy to imatinib； * BSA≤1.5m2； * Using other experimental drugs or participating in other clinical trials in the prior one months。